Good day everyone,

Jupiter Wellness, Inc. (NASDAQ: JUPW is engaged in research and development with a product pipeline addressing hair loss, eczema, burns, and sexual wellness.

Current price  $1.32/share (as of 10:40 a.m. EDT 11-15-22)

After closing the Tuesday session at $1.29, JUPW shares traded as high as $1.34/share early in the Wednesday session. There were 168K shares traded by the 10:40 AM. We expect the swing in JUPW’s value to continue.

My biggest takeaway from the Q3 earnings report this week was JUPW saying it will spin off their SRM division to their shareholders as its own separate NASDAQ traded company by year-end. Jupiter Wellness will remain the largest shareholder and the proposed transaction could happen before the end of the year.

Why would the company spin off the source of over 90% of its current revenue? I can think of two reasons:

JUPW will develop biopharma-based revenues beginning in Q4 2022. Their recent accretive acquisition of Applied biology came with a history of $8M in annual revenues. Add to that, revenues from the lucrative licensing deals recently negotiated with Taisho, in Japan, Cosmofix Technovation Pvt Ltd and Sanpellegrino Cosmetics in India. Both of those deals could start generating a steady stream of 2023 revenues.

Secondly, changing SRM into an independent NASDAQ listed company may help that company grow as funding for expansion could be more readily obtainable. That would be a benefit for both JUPW and its current shareholders.

Stay tuned. We have another potential runner coming this week.

The Traders News Group
original report below

Jupiter Wellness (JUPW) is Making Moves to Enhance Shareholder Value with a Recently Announced Dividend, Spin-Off and Lucrative Biopharma Deals

Revenues are growing and costs are down.

Good day everyone,

Jupiter Wellness, Inc. (NASDAQ: JUPW) is engaged in research and development with a product pipeline addressing hair loss, eczema, burns, and sexual wellness.

Current price $1.29/share (as of market close 11-15-22)

JUPW is a very interesting biopharma company and I expect 2023 may be their breakout year. The company generates revenue through the sales of OTC and consumer products, contract research agreements, licensing royalties, and through their subsidiary SRM. All these revenue streams are hitting stride in H2 this year and the company will record revenues in 2022 with the prospects for a breakout in 2023 looking good.

When I put all the pieces together and get a good grasp on the direction this company appears to be headed, it looks exciting. They’ve made some savvy accretive acquisitions, put together some lucrative licensing deals for their products, and aligned with world class distributors. I don’t think I’m the only one excited because JUPW shares are experiencing a nice swing right now that I think may just be starting.

Revenue growth:

FYE 2020             $1.0M
FYE 2021             $2.8M
FYE 2022             $7.0M (my estimate based on 9 mos. revenue of $5.2M)

On Monday, this week, JUPW released its Q3 results, here are some highlights:

Q3 22 revenues were $1,569,925 compared to $687,928 for the same period in 2021.
Operating expenses were $2,196,502, compared to $3,609,223 for the same period in 2021.
Net losses were $2,232,426 compared to $4,808,430 for the same period in 2021.
Director, Dr. Skender Fani, filed a Form 4 reporting the purchase of 122,000 shares on October 25.
JUPW signed an exclusive licensing agreement with Rejoy, Inc., to develop prescription products for the treatment of nipple neuropathies and associated sexual problems in women that have been treated for breast cancer.

Brian John, CEO of Jupiter Wellness, said, ” With combined sales orders shipped or received in the Third Quarter of over $5 million just coming off a record revenue in the Second Quarter, we are well on our way toward profitability by mid-2023.”

John continued, “We plan to file to spin off our SRM division to our shareholders as its own separate NASDAQ traded company by year-end. Jupiter Wellness will remain the largest shareholder while enabling us to access additional capital to grow the SRM business at a faster pace.”

The spin-off of SRM could be a real boon to shareholders operating as a separate company. With revenues already in place ($5.2M in the first 9 months of 2022), gross profit of $1M, and a backlog of $3.6M, SRM has the attributes to stand alone as a successful company. SRM has nothing to do with biopharma. JUPW acquired the company in November 2020, and it supplies the amusement park industry with exclusive products throughout the worldwide theme park industry.

JUPW clearly has their focus on developing a thriving biopharma-based business as the company’s most recent acquisitions, license agreements and partnerships have been in that sector and their focus is beginning to pay off. Read below to see everything the company has done in the biopharma sector.

Began their Contract Research Organization business – The JUPW CRO business was established through the acquisition of Ascent Clinical Research (ACR) assets in Q2 2022 and the accretive acquisition of Applied Biology (AB) assets in Q3 2022.
In 2021 AB recognized revenues of approximately $8M with $4M in EBITDA. For the ACR assets, the company has paid $1.3M to date and will receive 5% royalties on sales derived from the assets.

The JUPW biopharma product pipeline:

Photocil – Topical treatment for psoriasis and vitiligo (on the market)
It is anticipated that Photocil will be available online in the United States in Q4 2022 as an FDA-approved OTC product. See the recent events news about the huge India distribution deal below.

NoStingz – Topical protection from jellyfish, sea lice, and UVA/UVB rays (on the market)
NoStingz has been available online through Amazon and Walmart as well as in select stores starting in April-June 2022 with sales ramping up month-over-month.

Minoxidil Booster – Topical treatment designed to improve Minoxidil efficacy (on the market)
Licensed to Taisho, in Japan with a $300k up-front payment and 3% royalties on net sales. Also licensed to India-based Cosmofix Technovation Pvt Ltd and Sanpellegrino Cosmetics with a $50k up-front payment 10% royalties on net sales.

JW-100 – Topical treatment of eczema (in development)
Currently in a comparison study against EUCRISA by Pfizer with results expected in Q1 2023. See the latest news about the potential for this product below.

RJ-101 – Topical treatment for female sexual wellness (in development)
See the just announced licensing news with Rejoy, Inc. that I mentioned supplies the amusement park industry with exclusive products throughout the worldwide theme park industry.

JW-300 – Topical treatment of first-degree burns and sun exposure (in development)
A pre-revenue product and currently being evaluated.

JW-400 – Topical treatment of cold sores (in development)
A pre-revenue product. Clinical studies are needed before assessing a pathway to market.

Recent events at JUPW:

JUPW announced last week that it has re-opened enrollment in a clinical trial aimed at evaluating the superiority of JW-100, a novel cannabidiol topical cream, in a head-to-head study against EUCRISA, an FDA Approved topical treatment for eczema developed by Pfizer.
The continuation of the study is big news for the company because if JW-100 were to be found as effective or better than EUCRISA it could lead to a share of hundreds of millions in sales that Pfizer gets from their product. JUPW expects study completion in Q1 2023.

Earlier this month JUPW announced that its Photocil product (branded as PhotoFirst in India) has been approved by the CDSCO for sale in India. Photocil is a topical product that filters UV rays from the sun to allow only the therapeutic UV spectrum to penetrate the skin. It is used for the treatment of psoriasis and vitiligo. The commercial launch is expected to begin in Q1 2023. Distribution will be through Sanpellegrino Cosmetics Pvt Ltd & Cosmofix Technovation Pvt Ltd with whom JUPW signed a licensing agreement covering 31 countries.

JUPW has announced plans to transfer and spin off 40% of its wholly owned subsidiary, Caring Brands Inc, a developer of cann-a-bidiol based therapeutics and wellness products, by way of a dividend. Jupiter will maintain 60%. The dividend will be in the form of digital securities and will be transferred to shareholders with a record date to occur in late November.

JUPW statistics:

FYE is December 31^st – MRQ is September 30, 2022
Revenues (ttm)                $5.95M
Outstanding shares        21.6M
Shares in float                  15.8M
Cash (mrq)                       $3.5M
Insider ownership           43%
Market cap                       $26M

As the chart below indicates, JUPW shares have broken through all their SMA averages and are moving to new highs.

We will have an updated report soon,

The Traders News Group